Paracetamol 650,Paracetamol 500,Aceclofenac plus Parcetamol,Trypsin plus Chymotrypsin Tablets,Chlor
National Institute Of Technology (nit)
Bid Publish Date
29-Jan-2025, 3:33 pm
Bid End Date
22-Feb-2025, 4:00 pm
EMD
₹900
Location
Progress
Quantity
9620
Bid Type
Two Packet Bid
Public procurement opportunity for Indian Pharmacopoeia Commission (ipc) Adenosine, Apremilast, Ascorbic Acid - Vit. C, Benzylpenicillin Potassium, Bisoprolol fumarate, Brinzolamide, Bromhexine Hydrochloride, Caffeine, Carbimazole, Cefadroxil, Cefuroxime Sodium, Chlorpheniramine Maleate, Choline Fenofibrate, Cilnidipine, Cinnarizine, Ciprofloxacin Hydrochloride, Citric Acid, Clarithromycin, Clindamycin Hydrochloride, Clobazam, Clobetasol Propionate, Clomifene Citrate, Clonazepam, Clopidogrel Bisulphate, Clotrimazole, Cyanocobalamin - Vit. B12, Dapoxetine Hydrochloride, Diacerein, Diclofenac Diethylamine, Diclofenac Sodium, Domperidone Maleate, Dorzolamide Hydrochloride, Doxofylline, Dutasteride, Ebastine, Eberconazole Nitrate, Eslicarbazepine Acetate, Ezetimibe, Fenofibrate, Fluconazole, Folic Acid, Frusemide or Furosemide, Gentamicin Sulphate, Gliclazide, Hydrochlorothiazide, Imatinib Mesylate, Ivermectin, Lactulose, Lamivudine, Lansoprazole, L-Arginine Monohydrochloride, Lenvatinib Mesylate, Letrozole, Levofloxacin Hemihydrate, Levonorgestrel, Linezolid, Methylparaben, Methylphenidate Hydrochloride, Metoprolol Succinate, Metronidazole, Montelukast Sodium, Mupirocin, Neomycin Sulphate, Nicotinic Acid - Niacin, Olopatadine Hydrochloride, Omeprazole, Ornidazole, Pioglitazone Hydrochloride, Piroxicam, Potassium sucrose octasulphate, Prednisolone Acetate, Pregabalin, Pyridoxine Hydrochloride - Vit. B6, Quetiapine Fumarate, Risperidone, S - Amlodipine Besylate, Salbutamol Sulphate, Sofosbuvir, Sorbitol, Tacrolimus, Tamsulosin Hydrochloride, Terbinafine Hydrochloride, Thiamine Hydrochloride Vit B1, Timolol Maleate, Tocopheryl Acetate, Tranexamic Acid, Triamcinolone Acetonide, Ursodeoxycholic Acid, Vildagliptin, Xylometazoline Hydrochloride, Zoledronic Acid, Zopiclone, Imipenem monohydrate, Lithium Lactate, Mupirocin Lithium, 2 Methyl 5 nitroimidazole, Chlorobenzhydryl Piperazine, Fexofenadine impurity A, Pregabalin impurity D, Pregabalin impurity C, Paroxetine impurity A, Folic Acid impurity A, Valproic Acid impurity C, Miconazole related compound F, Miconazole related compound I, Propyl Paraben Impurity C, Montelukast Styrene, Pregabalin impurity A, Gabapentin impurity E, Pregabalin Lactam impuity, Noscapine impurity A, Benzothiadiazine impurity A, Aciclovir impuity B, Lamivudine impurity A, Lansoprazole impurity A or Lansoprazole sulphide, Baclofen impurity A in GHAZIABAD, UTTAR PRADESH. Quantity: 9620 issued by. Submission Deadline: 22-02-2025 16: 00: 00. View full details and respond.
Main Document
BOQ
BOQ
OTHER
OTHER
National Institute Of Technology (nit)
Border Road Organisation
KARGIL, JAMMU & KASHMIR
Directorate Of Medical Education And Research
OSMANABAD, MAHARASHTRA
Hqids
SOUTH ANDAMAN, ANDAMAN & NICOBAR
Hqids
SOUTH ANDAMAN, ANDAMAN & NICOBAR
Tender Results
Loading results...
Discover companies most likely to bid on this tender
Experience Criteria
Past Performance
Bidder Turnover
Certificate (Requested in ATC)
OEM Authorization Certificate
OEM Annual Turnover
Additional Doc 1 (Requested in ATC)
Compliance of BoQ specification and supporting document *In case any bidder is seeking exemption from Experience / Turnover Criteria
the supporting documents to prove his eligibility for exemption must be uploaded for evaluation by the buyer
Extended Deadline
22-Feb-2025, 4:00 pm
Opening Date
22-Feb-2025, 4:30 pm
| S.No | Seller | Item | Date | Status |
|---|---|---|---|---|
| 1 | ANALYTICA CHEMIE INC Under PMA | - | 19-02-2025 13:47:22 | Evaluated |
| 2 | AURIGA RESEARCH PRIVATE LIMITED Under PMA | - | 22-02-2025 13:07:12 | Evaluated |
| 3 | Cleanchem Laboratories LLP Under PMA | - | 21-02-2025 13:05:30 | Evaluated |
| 4 | DR.ASHAVIN'S LAB SERVICES (OPC) PRIVATE LIMITED Under PMA | - | 19-02-2025 14:59:02 | Evaluated |
| 5 | GLOBESYNTH PHARMA TECH Under PMA | - | 19-02-2025 11:55:19 | Evaluated |
| 6 | HONEYCHEM PHARMA RESEARCH PRIVATE LIMITED Under PMA | - | 18-02-2025 20:48:42 | Evaluated |
| 7 | SUBTLE PHARMACEUTICALS PRIVATE LIMITED Under PMA | - | 19-02-2025 13:47:36 | Evaluated |
Key insights about UTTAR PRADESH tender market
The eligibility requirements include being a registered entity capable of meeting the mandated experience criteria and demonstrating past performance. Bidders must also support their application with OEM authorization certificates and evidence of turnover as specified in the tender documentation. Every bidder is urged to provide relevant documentation supporting their claims of eligibility, especially if seeking exemption from any criteria.
Bidders must submit various certificates such as OEM authorization, compliance certifications noted in the terms and conditions, and proof of past performance. Applicants are also encouraged to include documentation that indicates their eligibility concerning the experience and turnover criteria as specified in the tender. It is essential to meet all certification requirements to ensure compliance with the procurement guidelines.
The Earnest Money Deposit (EMD) for this tender is set at 900. This deposit must accompany the bid submission as a demonstration of the bidder's seriousness and commitment to the procurement process. The EMD will be returned to all participants after the completion of the evaluation, barring any bidder disqualifications based on non-compliance or failure to adhere to the submission guidelines.
The evaluation process will follow an item-wise evaluation method, ensuring that each line item in the BoQ is reviewed based on technical and financial criteria. Bids will be scrutinized to assess compliance with the standards outlined in the tender documentation. Notification of results will be managed promptly to keep all bidders informed of their standing in the selection process.
Yes, the tender includes special provisions for Micro, Small, and Medium Enterprises (MSEs) and startups. These provisions are aimed at enhancing competitiveness and offering equal participation opportunities. Bidders are encouraged to leverage these benefits, ensuring all submissions comply with such outlined provisions for local content and procurement rules, including adherence to the 'Make in India' policies.
Sign up now to access all documents
Main Document
BOQ
BOQ
OTHER
OTHER